
Sign up to save your podcasts
Or
This week, we’re covering the FDA approval of a doublet therapy in certain populations of patients with newly diagnosed acute myeloid leukemia. Then we’ll hear about a comparison study of treatments for patients with metastatic breast cancer and brain metastases.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Ivosidenib/Azacitidine for Certain Patients With Newly Diagnosed AML
Etirinotecan Pegol vs Physician’s Choice of Chemotherapy for Patients With Metastatic Breast Cancer and Brain Metastases
To listen to more podcasts from ASCO, visit asco.org/podcasts.
4.5
1515 ratings
This week, we’re covering the FDA approval of a doublet therapy in certain populations of patients with newly diagnosed acute myeloid leukemia. Then we’ll hear about a comparison study of treatments for patients with metastatic breast cancer and brain metastases.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Ivosidenib/Azacitidine for Certain Patients With Newly Diagnosed AML
Etirinotecan Pegol vs Physician’s Choice of Chemotherapy for Patients With Metastatic Breast Cancer and Brain Metastases
To listen to more podcasts from ASCO, visit asco.org/podcasts.
116 Listeners
58 Listeners